PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 27, 2026Ophthalmology and Therapy3 citationsOpen Access

Real-World 6-Month Treatment Outcomes of Faricimab in Turkey: The FARTURK Study

AÇAkın ÇAKIRFAFevzi AkkanZKZiya Kapran

Key Points

  • The study aims to evaluate the effectiveness and safety of faricimab in real-world treatment of nAMD and DME over six months.
  • Conducted a six-month clinical study in Turkey
  • Analyzed real-world treatment data
  • Measured anatomical and functional outcomes
  • Assessed safety profile compared to phase III trials
  • Faricimab showed significant anatomical improvements within 15 days
  • Functional improvements were also observed over the six-month period
  • The safety profile was comparable to previous phase III trial results
  • Findings support faricimab as a viable treatment option for nAMD and DME

Abstract

Faricimab demonstrated rapid and significant anatomical and functional improvements in 6-month real-world data, evident as early as 15 days after the initial injection, with a safety profile comparable to phase III trials. These findings support faricimab as a potent and reliable therapeutic option in the real-world management of nAMD and DME, though extended follow-up is needed to assess long-term outcomes.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

ÇAKIR et al. (2026) studied this question.

synapsesocial.com/papers/69a134fbed1d949a99abe703https://doi.org/10.1007/s40123-026-01338-9
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Two-Year Real-World Outcomes of Faricimab for Diabetic Macular Edema in Japan2025 · 4 citations
  2. 2Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists2024 · 18 citations
  3. 3RETINAL VASCULAR CYSTOID MACULAR EDEMA2016 · 233 citations
  4. 4Molecular pathogenesis of retinal and choroidal vascular diseases2015 · 554 citations
  5. 5Outcomes of Anti-VEGF Therapy in Eyes with Diabetic Macular Edema, Vein Occlusion-Related Macular Edema, and Neovascular Age-Related Macular Degeneration: A Systematic Review2024 · 17 citations